ArticleMedicine2026
Pathological characteristics and HER2 status of gastric cancer in Chinese high-incidence area.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A retrospective analysis was conducted on the positive rate of HER2 in gastric cancer in the Chinese high-incidence area of Wuwei from 2015 to 2024. The pathological characteristics of HER2-positive gastric cancer were explored to provide a basis for precise diagnosis and treatment in high-incidence areas of gastric cancer. A retrospective study design was adopted to collect and analysis the HER2 expression status of gastric cancer surgical specimens from 2015 to 2024. A total of 416 gastric cancer surgical specimens were collected for HER2 detection, and the positive rate of HER2 was 9.13% (38/416), including 33 males (9.68%) and 5 females (6.67%), with no statistical significance (P >.05). There were 24 (8.63%) HER2 positive patients over 60 years old, 11 (10.67%) HER2 positive patients between 50 and 59 years old, and 3 (8.6%) HER2 positive patients under 50 years old, with no statistical significance (P >.05). In cTNM stages, HER2 was positive in 7 patients (5.65%) in stage Ⅰ, 16 patients (10.32%) in stage Ⅱ, 14 patients (10.61%) in stage Ⅲ, and 1 patient (20%) in stage Ⅳ, with no statistical difference between groups (P >.05). The positive rate of tubular adenocarcinoma HER2 in WHO classification was 10.5%. Other tissue types were 0%, there were differences (P <.05); The positive rate of HER2 in well-differentiated adenocarcinoma was 10.84%, in moderately differentiated adenocarcinoma 16.44%, and in poorly differentiated adenocarcinoma 8.25%, with a difference between moderately and poorly differentiated adenocarcinoma (P <.05). The positive rate of HER2 in T3 infiltration depth was 15.97% higher than that in T1/T2/T4 (P <.05). The positive rate of HER2 in cardiac/fundus was 16.26% higher than that in other sites (P <.05). The proportion of patients with intestinal stype gastric cancer was the largest in Lauren classification (59.13%), but the HER2 positive rate of mixed type was significantly higher than that of other Lauren classification (P <.001). Patients with lymph node metastasis (13%) were significantly higher than those without lymph node metastasis (4.66%), and the difference was statistically significant (P <.01). The research data indicate that correlation between the expression of HER2 in areas with a high incidence of gastric cancer and the pathological characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.